目的：研究重组人血管内皮抑制素（rhu-Endostatin）对小鼠Lewis肺癌肿瘤生长的抑制作用，寻找其量效关系及其作用机制。方法：每只小鼠剃毛背部皮下接种Lewis肺癌细胞，待肿瘤长至100 mm3左右时，随机分为低、中、高3个剂量组，每次分别注射rhu-Endostatin 5 mg/（kg·d）， 15 mg/(kg·d)或30 mg/（kg·d），每天1次，连续21 d。同时设置生理盐水对照组和注射用环磷酰胺\[100 mg/（kg·d）\]治疗对照组。于第22天断颈处死小鼠，称皮下肿瘤的重量，并取脑、肺、肝、脾和肾切片做病理学检查。结果： 血管内皮抑制素治疗组的曲线下面积明显小于肿瘤对照组（P<0.01）。病理切片检查显示，治疗组肿瘤有大面积的坏死，瘤周毛细血管消失。结论：rhu-Endostatin可明显抑制小鼠Lewis肺癌肿瘤的生长（高剂量组可达588%）、转移和新生毛细血管的形成。
Objective:To investigate the anti-tumor effect of recombinant human Endostatin (rhu-Endostatin)on the growth of mouse Lewis lung carcinoma cells, and to elucidate the dose-effect relationship and its possible mechanism. Methods:Lewis lung carcinoma cells were inoculated to mice (10 6-/ml). When trmor size reached about 100 mm3, the mice were randomly divided into low, medium and high dose groups with saline and CSA \[100 mg/（kg·d)\] as control. Rhu-Endostatin \[5,15, 30 mg/(kg·d)\] was injected to mouse once a day for 21days. At the 22 nd day, mice were executed, the tumor weights was calculated, and sections of brain, lung, liver, spleen and kidney was subjected to physiological analysis. Results: Area under curve in the endostatin-treated group was obviously less than that in tamor control group (P<0.01). Pathological study revealed that lavge areal necrosis arose in tumor and newborn capillaries around the tumor disappeared. Conclusion: The results revealed that rhu-Endostatin inhibited the growth, metastasis and angiogenesis of mouse Lewis lung carcinoma with the highest inhibition rate of 58.8%.